The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Isabl; Ocean Genomics; Xilis
Stock and Other Ownership Interests - Clovis Oncology; Gritstone Bio; Guardant Health; Isabl; Natera; Ocean Genomics; Xilis
Consulting or Advisory Role - Isabl; Ocean Genomics; Xilis
Travel, Accommodations, Expenses - Isabl; Ocean Genomics; Xilis
Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.
 
Anne C. Chiang
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi; Flatiron Health; Genentech; Genentech; Genentech/Roche; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Hossein Asghari
No Relationships to Disclose
 
Kerryan Ashley
Research Funding - AstraZeneca (Inst)
 
Scott N. Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); NextCure (Inst)
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Merck; Mirati Therapeutics; Regeneron; Summit Therapeutics; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Roy S. Herbst
Leadership - American Association for Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; AstraZeneca; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Gilead/Forty Seven; HiberCell; I-Mab; Immune-Onc Therapeutics; Janssen; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; NextCure; NextCure; Normunity; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Regeneron; Revelar; Ribon Therapeutics; Sanofi; Seagen; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Frederick Hugh Wilson
Consulting or Advisory Role - Loxo
Research Funding - Agios
 
Benjamin Robert Newton
No Relationships to Disclose
 
Michael Keith Cohenuram
No Relationships to Disclose
 
Kert D. Sabbath
No Relationships to Disclose
 
Ashita D. Talsania
No Relationships to Disclose
 
Armand Vincent Russo
No Relationships to Disclose
 
Eric Schultz
No Relationships to Disclose
 
Stan Skrzypczak
No Relationships to Disclose
 
Carl Kingsford
Leadership - Ocean Genomics
Stock and Other Ownership Interests - Ocean Genomics
Patents, Royalties, Other Intellectual Property - Provisional patent on biomarker development.
 
Kurt A. Schalper
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol Myers Squibb; CDR-Life; Clinica Alemana; EMD Serono; Molecular Templates; OnCusp Therapeutics; Parthenon Therapeutics; Roche; Shattuck Labs; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Forefront Collaborative; Genmab; Merck; Peerview; Takeda
Research Funding - Akoya Biosciences (Inst); AstraZeneca; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Lilly; Merck; Navigate BioPharma; Ribon Therapeutics; Roche (Inst); Surface Oncology; Takeda; Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Patent No. 16/464,010 (PREDICTION OF RESPONSE TO IMMUNE-MODULATORY THERAPIES)
Expert Testimony - AstraZeneca